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Abstract
Background: In a context of change in the demographic profile of the older population, to identify an age
threshold for increased risk and burden of herpes zoster (HZ) in 70+ patients.
Methods: Post hoc analysis of the 12-month French nationwide prospective observational ARIZONA cohort study.
HZ was assessed by means of the following validated questionnaires: Neuropathic Pain Symptom Inventory (NPSI), Zoster
Brief Pain Inventory (ZBPI), Short-Form health survey (SF-12), and Hospital Anxiety and Depression Scale (HADS).
Results: 644 general practitioners included 1,358 volunteer patients with acute HZ in the ARIZONA study; 609 patients
(45%) were 70+. In 70+ patients, age did not increase rash severity or HZ-related pain intensity at diagnosis, but increased
by 64% the frequency of ophthalmic zoster (from 5.5% in 70–74 years age-group to 9.0% in 85+ patients, p = NS). Age
was significantly associated with low physical health as assessed by the SF-12 Physical Component Summary (SF-12 PCS)
score and bad mood as assessed by the HADS depression score (p < 0.001). Within the year following HZ, post-herpetic
neuralgia (PHN) was systematically but not significantly more frequent in 85+ patients than in the 70–74, 75–79, or 80–84
years age-groups (19.0% vs. 13.3%/15.3%/11.6% at month 3; 15.1% vs. 7.3%/11.0%/12.2% at month 6; 15.2% vs. 6.0%/8.0%/
6.0% at month12, respectively). SF-12 PCS and HADS depression scores improved from day 0 to month 12 in all patients
(p < 0.001). 85+ patients were more impaired than younger patients (p < 0.001), but without clear difference according
to PHN.
Conclusions: This study did not show in 70+ patients a clear and significant age threshold at which disease burden
increased, although for some domains the impact seemed higher among the oldest patients; the cut-off of 70 years
remains thus relevant for clinical and epidemiological studies. However, at individual level, assessment of the burden of
HZ and HZ-related pain appears necessary to improve management and prevent functional decline in the most
vulnerable 70+ patients.
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Background
Herpes zoster (HZ) results from reactivation of varicella-
zoster virus (VZV) from a latent infection in the sensory
ganglia [1,2]. HZ affects peripheral nerves and induces
painful skin and nerve lesions. The acute phase is usually
defined as ≤1 month after rash onset, while post-herpetic
neuralgia (PHN), the most common complication, is often
defined as pain persisting for ≥3 months after rash onset [3].
In part due to the decline of cell-mediated immunity
with age, age is the major risk for developing both HZ
and HZ-related pain, including PHN [4-7]. Previous
studies suggested that HZ and PHN substantially impair
health-related quality of life (HRQoL), that PHN may
reduce the ability to maintain an independent lifestyle,
and that acute and chronic HZ-related pain may impair
activities of daily living, psychological well-being and social
interactions [8-13]. The real long-term burden of illness
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experienced by HZ patients, and in particular by older
patients, is not clearly known due to a lack of large-scale
longitudinal studies [14]. Such data are needed with the
expected increase in the number of people who will
develop HZ and HZ-related pain [11-15].
ARIZONA is a large prospective longitudinal cohort
study aiming to assess the real-life burden of HZ from the
patient’s perspective and the influence of age on disease
burden. It was conducted in France in patients aged 50-
years or more (50+) with acute HZ in the eruptive phase.
Its main results have been recently published [16]. Multi-
variate analysis of ARIZONA results has shown that age
70+ was an independent predictor of PHN at 3 months
and that HZ-related pain, including PHN, impaired daily
life functioning, HRQoL and mood. The age cut-off
(70 years) was selected for consistency with the efficacy
analysis of the Shingles Prevention Study, which compared
the incidence of HZ and PHN in two groups receiving
shingles (HZ) vaccine or placebo [17].
The world population is ageing. Moreover, the demo-
graphic profile of the older population is changing: the
proportion of persons aged 80 or over (80+) is projected
to increase almost fourfold over the next 50 years [18].
In this context, to determine an age threshold at which
HZ and PHN are particularly at risk for patients, includ-
ing beyond 70 years of age could be helpful to improve
patients’ management.
The objective of this complementary analysis, per-
formed on data from the most elderly ARIZONA patients
(i.e., 70+ only), was thus to determine whether, beyond
70 years, age remained a risk factor for PHN and in-
creased the burden of the disease, and whether a new age
threshold could be defined in the most elderly patients.
Methods
The longitudinal prospective multicentre observational
ARIZONA study was conducted in general practices in
France between 20 November 2006 and 12 September
2008. The study, managed by a multidisciplinary scientific
committee, was carried out in accordance with the princi-
ples of the Declaration of Helsinki (2004); approval was
provided by an independent French review board (CCTIRS
for Comité consultatif sur le traitement de l’information en
matière de recherche). All patients provided written
informed consent before enrolment. The study methods
were published in detail in 2012 [16].
Briefly, 644 of the 29,177 general practitioners (GPs)
randomly selected from the list of GPs practicing in
France and contacted by post agreed to participate in
the study and included at least one patient. Each GP
included consecutively all 50+ patients with acute HZ in
the eruptive phase if (1) they were seen within 7 days of
rash onset and (2) they had good understanding of
French and telephone access. Eruptive phase was defined
as visible skin lesions at any stage of development.
Patients with HZ in the preceding 12 months or partici-
pating in any clinical trial were excluded. The study was
managed by a multidisciplinary scientific committee.
The protocol was approved by an Ethics Committee. All
patients gave written informed consent.
At the inclusion consultation (day 0), the GP documented
the subject’s demographic and medical characteristics, HZ
characteristics, and currently prescribed drugs. Rash sever-
ity was assessed by the GP based on quantitative and quali-
tative assessment of lesions.
The baseline questionnaire was to be completed by the
patients at the GP’s office during the recruitment consult-
ation or at home within a day of the consultation. It com-
prised a dedicated form assessing the patient’s perception
of HZ-related pain and four validated self-reported ques-
tionnaires: the Neuropathic Pain Symptom Inventory
(NPSI) [19]; the Zoster Brief Pain Inventory (ZBPI) [9,20];
the 12-item Short-Form health survey (SF-12) [21]; and
the Hospital Anxiety and Depression Scale (HADS) [22].
The NPSI assesses the severity of each of the 10 symp-
toms of neuropathic pain on a scale ranging from 0 (no
pain) to 10 (worst pain imaginable) [19]. On the global
NPSI score, mild pain is defined by scores ranging be-
tween 0 and 29, moderate pain by scores ranging between
30 and 79, and severe pain by scores ranging between 80
and 100. The ZBPI rates the severity of pain on a scale
ranging from 0 (no pain) to 10 (pain as bad as you can im-
agine), and the interference of pain on the activities of
daily life on a scale ranging from 0 (does not interfere) to
10 (completely interferes); mild interference is defined by
scores ranging between 0 and 2, moderate interference by
scores ranging between 3 and 4, and severe interference
by scores ranging between 5 and 10 [9,20]. The Physical
Component Summary (PCS) score and the Mental
Component Summary (MCS) scores were calculated from
the SF-12 [21]. SF-12 PCS or MCS scores <50 indicates
HRQoL impairment (range score: 0–100). HADS anxiety
or depression scores above 8 indicate anxiety or depres-
sion [22].
During the follow-up period (months 3, 6 and 12), pa-
tients were contacted by telephone and completed a
follow-up questionnaire with the help of a trained inter-
viewer, comprising the same dedicated form and question-
naires. PHN was defined as the persistence of pain of any
intensity 3 months or more after the rash onset.
All statistical analyses were performed using version
8.02 SAS software (SAS Institute, Inc., Cary, NC, USA).
For this complementary analysis, quantitative variables
were described by frequency, mean, standard deviation
(SD), median and range, according to four (70–74, 75–79,
80–84, and 85+ years) and two (70–79 and 80+ years)
age-groups, or to two groups defined by PHN (with or
without) at months 3, 6, and 12. The four age-groups have
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been defined based on the 85+ age-group (i.e., currently
considered as the ‘old old’) in order to have a similar
number of patients in each age-group. Results based on
the two age-groups are disclosed only when they brought
additional information to the comparison made on the
four age-groups. Qualitative variables were described by
frequency and percentage of each modality. Fisher, Chi2, or
Wilcoxon tests were used to compare groups. Regression
analysis for repeated measures was used to assess the
impact of age on score evolution over time (day 0 and
months 3, 6 and 12) and the influence of age on each
parameter regardless of time.
Results
Participants
644 GPs enrolled in the ARIZONA study 1,517 patients
aged 50 years and over, of whom 1,358 satisfied the
inclusion criteria. Out of these 1,517 patients, 609 (45%)
were 70+ and were included in the present complementary
analysis: 383 patients (62.9%) were between 70 and 79 years
of age and 226 (37.1%) were 80+; respectively, 220 (36.1%),
163 (26.8%), 137 (22.5%), and 89 patients (14.6%) belonged
to the 70–74, 75–79, 80–84, and 85+ age-groups.
Table 1 presents the main baseline characteristics of
the elderly patients in each of the four age-groups. In all
age-groups, there were more women than men. Comor-
bidity (mainly cardiovascular disease) was frequent in all
age groups (>70%).
HZ characteristics at baseline
Table 2 presents HZ characteristics at baseline. The
time-interval between rash onset and HZ diagnosis was
commonly ≤2 days in all age-groups. Rash severity did
not qualitatively or quantitatively increase with age after
70 years. Ophthalmic zoster location was more frequent
in the most elderly patients although the difference
between age-groups was not significant (p = 0.57): the
frequency of ophthalmic zoster ranged from 5.5% in the
70–74 age-group to 9.0% in the 85+ age-group.
HZ-related pain, whose onset always slightly preceded
rash onset in all age-groups, was frequent at baseline
(reported by about 80% of patients, n = 486). It was of
moderate intensity without difference between age-groups:
mean NPSI score around 30 and mean worst pain ZBPI
severity score around 5 in all age-groups (Table 2). Burning
pain was the main descriptor (data not shown).
Table 1 Main baseline characteristics of patients (70+) included in the ARIZONA study
Age (years) 70-74 (N = 220) 75-79 (N = 163) 80-84 (N = 137) 85+ (N = 89) p- value
Sex (female): % 60.9 61.3 61.0 76.1 0.062
BMI (kg/m2): mean (SD) 26.6 (4.8) 26.6 (4.6) 24.9 (4.0) 25.4 (4.4) 0.001
Comorbidity: % 72.8 78.4 81.5 78.7 0.261
Cardiovascular disease 63.3 73.2 80.9 78.6 0.008
Diabetes 13.3 17.3 4.5 11.4 0.324
Cancer 8.2 11.0 8.6 11.0 0.263
Chronic pulmonary disease 10.1 12.6 10.9 14.3 0.801
Other chronic disease 33.5 24.4 28.2 25.7 0.351
Previous history of VZV disease: %
Known history of varicella 51.1 48.1 41.6 45.5 0.642
Known history of Herpes zoster 20.5 17.9 16.1 11.2
If history of VZV disease: % 0.663
≥12 and <24 months 9.3 10.3 4.5 0.0
>24 months 90.7 89.7 92.5 100.0
Familial status: % <0.001
Married or partner 67.9 63.4 45.5 32.4
Widowed 21.2 26.1 43.0 59.5
Divorced or separated 6.2 7.0 5.0 2.7
Single 4.7 3.5 6.6 5.4
Living conditions: % <0.001
At home or with close relatives 96.9 97.9 91.7 82.7
In a community 3.1 2.1 8.3 17.3
BMI = body mass index; SD = standard deviation; VZV = varicella zoster virus.
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98.5% of patients had at least one medical prescription,
mainly antiviral drugs (94.7%) and analgesics (86.5%).
The percentage of patients under treatment did not
differ with age.
Impact of HZ and HZ-related pain on daily life, HRQoL,
and mood at baseline
Results are presented in Table 3. At baseline, HRQoL,
and mood were impaired in all age-groups: mean ZBPI
interference scores were around 3, mean SF-12 PCS and
MCS scores were below 50, and mean HADS depression
scores close to 8.
No significant difference was found in mean ZBPI inter-
ference scores between the four age-groups (p = 0.582).
As regards HRQoL, SF-12 PCS scores decreased signifi-
cantly with age (p < 0.001), indicating greater HRQoL
impairment in the most elderly patients. The low SF-12
PCS scores observed in the 85+ age-group were mainly
due to the scores of the ‘physical functioning’ and ‘vitality’
dimensions. No statistically significant difference in SF-12
MCS scores was observed between the four age groups
(p = 0.413).
As regards mood, HADS depression scores increased
significantly with age (p < 0.001), indicating greater
mood impairment in the most elderly patients. No sta-
tistically significant differences in HADS anxiety scores
were observed between the four age groups (p = 0.237).
Change in HZ-related pain, daily life, HRQoL, and mood
from day 0 to month 12
Figure 1 presents the percentage of patients who reported
HZ-related pain from day 0 to month 12. Prevalence of
HZ-related pain dramatically decreased between day 0
and month 3 in all age-groups: overall, 66 patients (14.3%)
had PHN at month 3. Prevalence of PHN slightly
decreased from months 3 to 12: 30 patients (7.6%) had
Table 2 Main baseline characteristics of herpes zoster and herpes zoster-related pain in each age-group
Age group (years) 70-74 (N = 220) 75-79 (N = 163) 80-84 (N = 137) 85+ (N = 89) p-value
Time-interval between rash onset and
herpes zoster diagnosis: %
0.179
≤1 day 46.3 34.6 41.9 37.9
>1 and ≤2 days 22.7 22.2 24.3 31.0
>2 and ≤3 days 14.8 16.0 14.0 16.1
>3 days 16.2 27.2 19.9 14.9
Rash location: % 0.070
Cranial, cervical, facial, and/or ophthalmic 15.0 16.6 19.0 28.1
Thoracic, abdominal and/or sacrolumbar 72.3 66.3 62.8 61.8
Upper and/or lower limbs 8.2 11.7 8.0 5.6
Other location and/or combination of
previous locations
4.5 5.5 10.2 4.5
Rash severity (quantitative assessment): % 0.775
Few vesicles 43.9 38.9 43.5 41.2
Many vesicles (extensive rash) 56.1 61.1 56.5 58.8
Rash severity (qualitative assessment): %
Simple vesicles 86.9 80.3 85.5 81.2 0.294
Haemorrhagic lesions 7.9 6.4 7.6 12.9 0.328
Necrotic lesions 3.7 12.1 6.1 4.7 0.650
Ophthalmic zoster 5.5 8.0 8.8 9.0 0.574
Time interval between pain and HZ vesicles onset:
mean (SD) (days)
−1.0 (2.3) −0.9 (2.5) −0.8 (2.4) −0.7 (2.1) 0.639
NPSI*: mean (SD) 32.7 (18.5) 29.9 (21.6) 31.1 (18.5) 33.3 (18.0) 0.407
ZBPI†: worst pain severity score, mean (SD) 5.4 (2.5) 5.1 (2.8) 5.8 (2.6) 5.5 (2.6) 0.185
Medical treatment: yes (%) 97.7 98.2 100 98.9 0.337
Antiviral drug 96.3 93.1 92.7 96.6 0.318
Analgesics 85.6 86.3 88.3 86.4 0.907
NPSI = Neuropathic Pain Symptom Inventory; SD = Standard deviation; ZBPI = Zoster Brief Pain Inventory.
*NPSI score > 30 indicates moderate pain.
†from 0, no pain to 10, maximal pain.
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PHN at month 12. At months 3, 6 and 12, the percentage
of patients with PHN was always higher in the 85+ than
in the other age-groups. However, no statistically signifi-
cant difference was found between the four age-groups
(p = 0.58, p = 0.34, and p = 0.24, respectively).
Figure 2 presents mean NPSI scores from day 0 to month
12 in each age-group in patients who reported HZ-related
pain (day 0) or PHN (months 3, 6 and 12). Pain intensity
assessed by NPSI decreased significantly between day 0 and
month 3, and then decreased slightly between months 3
and 12 in all age-groups except for the 85+ age-group at
month 6 and the 80–84 age-group at month 12, leading to
a statistically significant interaction between time and age
(p = 0.01).
Table 3 Burden of herpes zoster and herpes zoster-related pain at baseline in each age-group
Age group (years) 70-74 (N = 220) 75-79 (N = 163) 80-84 (N = 137) ≥85 (N = 89) p-value
ZBPI score: mean (SD)
Interference score* 3.2 (2.3) 3.1 (2.4) 3.5 (2.3) 3.6 (2.7) 0.582
SF-12†
PCS score: mean (SD) 42.7 (8.9) 41.8 (9.4) 37.9 (10.0) 34.2 (8.9) <0.001
Physical functioning 57.9 (35.3) 53.8 (34.9) 40.7 (34.2) 26.6 (33.6) <0.001
Vitality 36.6 (25.7) 33.5 (23.0) 28.8 (23.5) 25.4 (23.0) 0.004
MCS score: mean (SD) 41.1 (10.2) 38.7 (11.5) 39.6 (10.9) 41.0 (9.8) 0.413
HADS: mean (SD)‡
Depression score 6.3 (4.0) 7.9 (4.4) 8.1 (5.2) 9.8 (4.9) 0.001
Anxiety score 6.9 (4.2) 7.9 (4.1) 7.3 (4.6) 7.1 (4.3) 0.237
HADS = Hospital Anxiety and Depression Scale; MCS =Mental component summary; PCS = Physical component summary; SD = Standard deviation; SF-12 = 12-item
Short-Form health survey; ZBPI = Zoster Brief Pain Inventory.
*From 0, no interference to 10, maximal interference.
†Scores < 50 indicates health-related quality of life (HRQoL)impairment.
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Figure 1 Percentage of patients with herpes zoster (HZ)-related pain during the 12-month follow-up period in each age-group.
Percentages were calculated on available data.
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During follow-up, ZBPI interference scores in patients
with HZ-related (day 0) or PHN (months 3 to 12)
remained high (around 3), with no difference between
age-groups (data not shown).
Figure 3 presents mean SF-12 PCS and MCS scores
from day 0 to month 12 in each age-group. SF-12 PCS
scores increased slightly, from day 0 to month 12, in all
age groups (p < 0.001), indicating slight improvement in
HRQoL. These results were always driven by the ‘phys-
ical functioning’ and ‘vitality’ scores (data not shown).
In addition, at each time point, SF-12 PCS scores were
lower in the 85+ age-group than in the other age-
groups (p < 0.001), indicating greater HRQoL impair-
ment in the most elderly patients. Comparison within
the 85+ age-group found a significant difference in SF-
12 PCS scores between patients with and without PHN
at month 3 (mean +/− SD: 27.0 +/− 11.26 and 37.6 +/−
12.26, respectively; p = 0.015), but not at months 6 and
12 (p = 0.956, and p = 0.919, respectively), indicating
that impact of age and its comorbidities prevails over
consequences of PHN. Regarding SF-12 MCS summary
scores, from day 0 to month 12, SF-12 MCS scores in-
creased in all age-groups (p < 0.001), indicating an im-
provement in HRQoL, without statistically significant
difference in SF-12 MCS scores according to age
(p = 0.27).
Figure 4 presents mean HADS depression and anxiety
scores from day 0 to month 12 in each age-group.
HADS depression scores decreased from day 0 to month
12, in all age-groups (p < 0.001), indicating mood im-
provement. In addition, at each time point, HADS de-
pression scores were greater in the 85+ age-group than
in the other age-groups (p < 0.001), indicating greater
mood impairment in the most elderly patients. Com-
parison within the 85+ age-group found no significant
difference in HADS depression scores between patients
with and without PHN at months 3, 6, and 12 (p = 0.52,
p = 0.83, and p = 1.00, respectively), indicating that the
impact of age prevails over consequences of PHN.
However, when patients were classified into two age-
groups, in the 80+ age-group, HADS depression scores
significantly differed between patients with and with-
out PHN at months 3 and 12 (p = 0.01, and p = 0.04,
respectively) but not at month 6 (p = 0.30). HADS
anxiety scores decreased from day 0 to month 12, in all
age-groups (p < 0.001), indicating mood improvement,
without statistically significant difference according to




































Figure 2 Mean NPSI scores in patients with herpes zoster (HZ)-related pain during the 12-month follow-up period by age-group.
NPSI = Neuropathic Pain Symptom Inventory. NPSI score >30 indicates moderate pain (range score 0–100). Mean NPSI scores were calculated in
the population of patients aged 70 years or more with HZ-related pain (day 0) or PHN (months 3, 6, and 12) and available NPSI data at each
time-point. Missing data were not replaced.
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Figure 3 (See legend on next page.)
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Discussion
In the ARIZONA study, which is to our knowledge the
largest and longest prospective study to assess HZ bur-
den in patients aged 50 years or more (50+), it was pre-
viously shown that age ≥70 years was a risk factor for
both PHN and impaired HRQoL [16]. In a context of
ageing of the older European population, the objectives
of this post hoc analysis of the data collected during the
ARIZONA study was to determine whether, beyond
70 years, age remained a risk factor for PHN and in-
creased the burden of the disease, and whether a new
age threshold could be defined in the most elderly
patients.
Frequency and severity of pain during the acute phase of
HZ infection
Older age has long been considered as a risk factor for
severe pain during the acute phase of HZ infection [3].
In the entire ARIZONA cohort, we showed that at base-
line the proportions of patients with extensive rash or
haemorrhagic or necrotic lesions were higher in patients
70+. By contrast, no difference between groups of pa-
tients was observed in the frequency or severity of HZ-
related pain at inclusion [16]. In the MASTER study
[23-25], older age also ‘emerged as an independent pre-
dictor of greater severity-of-illness over 180 days, but
not during the first 90 days after rash onset’. According
to the authors, this result indicated that younger patients
were as likely as older patients to experience consider-
able burden during the acute phase of HZ, but had a
lower risk of developing PHN and consequently experi-
encing lower severity-of-illness over the entire episode.
The present results confirm that, in patients 70+, the in-
cidence of HZ-pain during the acute phase was large
and similar in all age groups: regardless of age, approxi-
mately 80% of them reported HZ-related pain. Our data
also indicate that there is no specific age cut-off after
70 years of age at which the frequency or intensity of
pain during the acute phase of HZ infection is further
increased. However, this analysis shows that the ophthal-
mic location of HZ infection tended to increase with
age, from 5.5% in the 70+ group to 9% in the 85+ group.
Frequency and severity of PHN
Depending on the time-frame used in the literature,
PHN occurs in 5% to more than 30% of patients [26].
Several possible risk-factors such as age, immunodepres-
sion, prodromal pain, and ophthalmic zoster have been
considered [25]. PHN, defined as HZ-related pain per-
sisting ≥3 months, was reported by about 30% of 70+
patients in an Icelandic study [27], 13% of 70+ patients
in the ARIZONA study, and 45% of patients in the
MASTER study [23-25]. After one year, 15% of 70+ pa-
tients in the Icelandic and 8% of the same age class in
the ARIZONA study still had pain. The percentage of
subjects with PHN was lower in the ARIZONA study
than in the MASTER study. In the ARIZONA study
[16], however, antiviral drugs were prescribed to 94.1%
of patients for a median 7 days, which may have contrib-
uted to reduce the intensity of acute pain, accelerate ves-
icular rash healing and reduce acute-phase viral
excretion duration [28]; conversely, in the MASTER
study [23], only 26% of included patients received anti-
viral medication at the recommended dose and time. Al-
though the efficacy of antiviral medication in PHN
prevention is controversial [29], it may thus be hypothe-
sised that early initiation of adequate treatment may
have contributed to the lower prevalence of related pain
at 3 months as compared with the MASTER study
[23-25]. These findings nevertheless support the need
for preventive vaccine strategies in elderly patients since
more than 1 in 10 patients will develop PHN even with
adequate treatment. Vaccination was shown to reduce
the incidence of HZ and PHN and the HZ burden of ill-
ness (a composite end point sensitive to the incidence,
severity and duration of HZ pain), to have a good safety
profile [17,30], and to be cost effective in elderly patients
[31,32]. Centers of Disease Control and Prevention
(CDC) recommended HZ vaccine for prevention of HZ
and its complications among adults aged 60 years or
more [33].
According to the literature, older age is an independ-
ent factor of PHN [3-7]. The ARIZONA study showed
that older age (70+) at baseline was an independent
predictive factor for PHN [16]. Severity of HZ-related
pain was comparable for 70+ patients and younger, but
the prevalence was significantly higher for 70+ patients
at months 1, 3, 6, and 9 and close to significance at
month 12. The present data showed that the percentage
of patients with persistent HZ-related pain at months 3,
6, and 12 was systematically but not statistically signifi-
cantly higher in the most elderly patients (i.e. 85+).
Pain intensity appeared to remain constant in patients
with persistent HZ-related pain (regardless of age). This
additional result was partly consistent with that of the
Canadian MASTER study, which found that mean pain
(See figure on previous page.)
Figure 3 Mean SF-12 PCS (a) and MCS (b) scores during the 12-month follow-up period by age-group. MCS =Mental Component
Summary; PCS = Physical Component Summary; SF-12 = 12-item Short-Form health survey. SF-12 MCS or PCS score <50 indicates quality of life
impairment [mean (standard deviation) score in the general 1998 U.S. population was 50 (10)] [12]. Mean MCS and PCS scores were calculated in
the whole population of patients aged 70 years or more with available data at each time-point. Missing data were not replaced.
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Figure 4 HADS depression (a) and anxiety (b) scores during the 12-month follow-up period by age-group. HADS: Hospital Anxiety and
Depression Scale. Score >8 indicates depression or anxiety. HADS scores were calculated in the whole population of patients aged 70 years or
more with available data at each time-point. Missing data were not replaced.
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intensity decreased during the first month of the disease
and then remained stable from months 1 to 6 [23]. In
addition, no clear difference in the severity of PHN was
observed according to age. This can possibly be partly
explained by a negative influence of age on perceived
degree of pain, as shown in acute myocardial ischemia
as being a possible cause for delayed treatment in elderly
patients, with a similar cut-off at 69 years [34].
Disease burden
It has been previously described that the PCS score of the
SF-12 shows impairment with age, and that HZ infection
severely impacts HRQoL [35,36]. In addition, it has been
recently showed that an episode of HZ could lead to
comorbidity decompensation and could jeopardize the
health status of an older person with concomitant
diabetes, COPD, or cardiovascular disease [37]. An im-
pairment of HRQoL due to both age and PHN could thus
be expected in the oldest patients in the ARIZONA study.
In fact, only the physical component of HRQoL as
assessed by the SF-12 PCS and depression as assessed by
the HADS were impacted by age. Indeed, the difference
over 8 points of baseline SF-12 PCS score between 85+
and 70–74 age groups exceeds the minimal important
difference of 3 points, by a meaningful [12].
This study showed that the older the patient, the lower
the SF-12 PCS score and the higher the depression
HADS score but failed to find clear difference in SF-12
PCS and HADS depression scores between patients with
and without PHN at months 3, 6, and 12. It may be thus
suggested that the impairment of HRQoL was related
more to age and its comorbidities than to the HZ infec-
tion per se.
However, the absence of significant difference can also
be explained by some of the limitations in this our study.
A selection bias cannot be ruled out as only data from
patients who agreed to participate in the study were col-
lected. However, the mean number of included patients
per GP was consistent with the mean number of patients
seen in general practice for HZ according to the French
GPs Sentinelles network (https://websenti.u707.jussieu.
fr/sentiweb/?page=presentation), indicating that almost
all patients seen for HZ by a GP agreed to participate in
the study. The second limitation is the small sample size
and heterogeneity of the different age-groups (although
as a whole, the sample size of ARIZONA cohort was
large, with over 1,350 patients), which may not be suffi-
cient to detect any effect. However, similar results were
usually observed when patients were classified into two
larger age-groups (70–79 and 80+). Finally, although the
frailty risk increases with age, the population of 70+ pa-
tients is probably highly heterogeneous: both well and
frail patients with various chronic diseases are included
in each age-group. That is why it is difficult to separate
influence of HZ and age and chronic diseases. Further
longitudinal studies with a large number of very old
patients assessing chronological and physiological ages or
frailty are thus needed to evaluate HZ and PHN burden in
the 70+. Indeed, beyond the age of 70 years, HZ and PHN
can impair frail patients. In the model by Rockwood et al.,
frailty can be thought of as a dynamic balance between
assets which help maintain a person’s independence and
deficits which threatens a person’s self-sufficiency or func-
tional capacity. In frail elderly, HZ and PHN can tip the
balance in favour of the deficit [38].
Conclusion
There is no definite age threshold at which HZ severity,
PHN frequency, pain intensity or disease burden as
assessed by validated scales increased in patients aged
70 years or more. At population level, the cut-off of
70 years remains thus relevant for clinical and epidemio-
logical studies. However, beyond the age of 70 years, HZ
and PHN can impair frail patients. At individual level,
assessment of the burden of HZ, HZ-related pain, and
PHN on daily life, quality of life and mood in elderly
patients appears necessary to improve their management
and prevent functional decline.
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